Mixed anxiety and depression: Diagnosis and treatment options

CNS Drugs

Volumn 9, Issue 4, 1998, Pages 271-280

  Bakish, David ^a,b   Habib, Rami ^a,b   Hooper, Cynthia L ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b ROYAL OTTAWA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; AZAPIRONE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ANXIETY NEUROSIS; ARTICLE; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DISEASE CLASSIFICATION; DRUG INDICATION; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HUMAN; NEUROLOGIC DISEASE; ORTHOSTATIC HYPOTENSION; PANIC; PRACTICE GUIDELINE; PRIORITY JOURNAL; SWEATING; SYMPTOMATOLOGY; TREMOR; XEROSTOMIA;

EID: 0031895638     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199809040-00003     Document Type: Article

References (69)

1. Robins LN, Locke BZ, Regier DA. An overview of psychiatric disorders in America. In: Robins LN, Regier DA, editors. Psychiatric disorders in America: the Epidemiologic Catchment Area Study. New York: Free Press, 1991: 328-66
2. Kessler RC, Nelson CB, McGonagle KA, et al. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry 1996; 168 Suppl. 30: 17-30
3. Angst J, Merikangas KR, Scheidegger P, et al. Recurrent brief depression: a new subtype of affective disorder. J Affect Disord 1990; 19: 87-98
4. Angst J, Vollrath M, Merikangas KR, et al. Comorbidity of anxiety and depression in the Zurich Cohort Study of young adults. In: Maser JD, Cloninger CR, editors. Comorbidity of mood and anxiety disorders. Washington, DC. American Psychiatric Press, 1990: 123-37
5. Ball SG, Buchwald AM, Waddell MT, et al. Depression and generalized anxiety symptoms in panic disorder: implications for comorbidity. J Nerv Mem Dis 1995; 183: 304-8
6. Blazer D, Schwartz M, Woodbury M, et al. Depressive symptoms and depressive diagnoses in a community population: use of a new procedure for analysis of psychiatric comorbidity. Arch Gen Psychiatry 1988; 45: 1078-84
7. Breslau N, Davis GC, DSM-III generalized anxiety disorder: an empirical investigation of more stringent criteria. Psychiatr Res 1985; 14: 231-8
8. Breslau N, Davis GC. Further evidence on the doubtful validity of generalised anxiety disorder [letter]. Psychiatr Res 1985; 16: 177-9
9. Cassano GB, Michelini S. Pharmacological treatment of depression and comorbid anxiety disorders. Adv Biochem Psychopharmacol 1995; 49: 113-25
10. Katon W, Roy-Byrne PP. Mixed anxiety and depression. J Abnorm Psychol 1991; 100: 337-45
11. Barrett JE, Barrett JA, Oxman TE, et al. The prevalence of psychiatric disorders in a primary care practice. Arch Gen Psychiatry 1988; 45: 1100-6
12. Liebowitz MR. Treating the patient with depression and associated anxiety. In: Serotonin - Reshaping the Treatment of Depression. MEDICINE Publishing Foundation Symposium Series, 32. Toronto: The Medicine Group (Canada) Ltd., 1992: 31-41
13. Boulenger J-P, Lavallée Y-J. Mixed anxiety and depression: diagnostic issues. J Clin Psychiatry 1993; 54 Suppl. 1: 3-8
14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed. rev. Washington, DC: American Psychiatric Association, 1987
15. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994
16. Hamilton M. Frequency of symptoms in melancholia (depressive illness). Br J Psychiatry 1989; 154: 201-6
17. Fava GA, Grandi S, Zielezny M, et al. Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry 1994; 151: 1295-9
18. Stahl SM. Mixed anxiety and depression: clinical implications. J Clin Psychiatry 1993; 54 Suppl. 1: 33-8
19. World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and guidelines. Geneva: WHO, 1992
20. Wittchen HU, Essau CA. Comorbidity and mixed anxiety-depressive disorders: is there epidemiologic evidence? J Clin Psychiatry 1993; 54 Suppl. 1. 9-15
21. Thase ME, Simons AD, McGreary J, et al. Relapse after cognitive behavioral therapy of depression: potential implications for longer course of treatment. Am J Psychiatry 1992; 149: 1046-52
22. Keller MB, Hanks DL. Anxiety symptom relief in depression treatment outcomes. J Clin Psychiatry 1995; 56 Suppl. 6: 22-9
23. Zajecka JM, Ross JS. Management of comorbid anxiety and depression. J Clin Psychiatry 1995; 56 Suppl. 2: 10-3
24. Kahn RJ, McMair DM, Lipman RS, et al. Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients. Arch Gen Psychiatry 1986; 43: 79-85
25. Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry 1988; 49: 293-301
26. Johnstone EC, Cunningham Owens DG, Frith CD, et al. Neurotic illness and its response to anxiolytic and antidepressant treatment. Psychological Med 1980; 10: 321-8
27. Rickels K, Cdanalosi I, Chung HR, et al. Amitriptyline in anxious-depressed outpatients: a controlled study. Am J Psychiatry 1974; 131 (1): 25-30
28. Rickels K, Schweizer B. The treatment of generalized anxiety disorder in patients with depressive symptomatology. J Clin Psychiatry 1993; 54 Suppl.: 20-3
29. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988; 45: 129-37
30. Quitkin FM, Stewart JW, McGrath PJ, et al. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry 1988; 145: 306-11
31. Versiani M, Mundim FD, Nardi AE, et al. Tranylcypromine in social phobia. J Clin Psychopharmacol 1988; 8: 279-83
32. Liebowitz MR, Quitkin FM, Stewart JW, et al. Effect of panic attacks on the treatment of atypical depressives. Psychopharmacol Bull 1985; 21 (3): 558-61
33. Lydiard RB. Co-existing depression and anxiety: special diagnostic and treatment issues. J Clin Psychiatry 1991; 52 Suppl. 6: 48-54
34. Angst J, Stabl M. Efficacy of moclobemide in different patient groups: a meta-analysis of studies. Psychopharmacology 1992; 106 Suppl.: 109-3
35. Fitton A, Faulds D, Goa KL. Moclobemide: a review of its pharmacological properties and therapeutic use in depressive illness. Drugs 1992; 43 (4): 561-96
36. Bakish D, Saxena BM, Bowen R, et al. Reversible monoamine oxidase A inhibitors in panic disorder. Clin Neuropharmacology 1993; 16 (2 Suppl.): 77S-82S
37. Johnson MR, Lydiard RB, Ballenger JC. MAOIs in panic disorder and agoraphobia. In: Kennedy SH, editor. Clinical advances in monoamine oxidase inhibitor therapies. Washington, DC: American Psychiatric Press, Inc., 1994: 205-24
38. Versiani M, Nardi AE, Mundim FD, et al. Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. Br J Psychiatry 1992; 161: 353-60
39. Bakish D. The use of the reversible monoamine oxidase-A inhibitor brofaromine in social phobia complicated by panic disorder with or without agoraphobia. J Clin Psychopharmacol 1994; 14 (1): 74-5
40. Wakelin J. Differential effects of fluvoxamine, imipramine and placebo on anxiety in depression [abstract]. 16th Congress Collequium Internationale Neuropsycho-pharmacologicum: 1988; Munich
41. Dunbar GC, Fuell DL. The anti-anxiety and anti-agitation effects of paroxetine in depressed patients. Int Clin Psychopharmacol 1992; 6 Suppl. 4: 81-90
42. den Boer JA, Westenberg GM. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988; 3: 59-74
43. Roy-Byrne P, Wingerson D, Cowley D, et al. Psychopharmacologic treatment of panic, generalized anxiety disorder, and social phobia. Psychiatr Clin North Am 1993; 16 (4): 719-35
44. Montgomery S, McIntrye M, Osterheide R, et al. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur Neuropsychopharmacol 1993; 3 (2): 143-52
45. McDougle CJ, Goodman WK, Leckman JF, et al. The psychopharmacology of obsessive compulsive disorder: implications for treatment and pathogenesis. Psychiatr Clin North Am 1993; 16 (4): 749-66
46. Louie AK, Lewis TB, Lannon RA. Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 1993; 54: 435-8
47. Sternbach H. Fluoxetine treatment of social phobia. J Clin Psychopharmacol 1990; 10 (3): 230-1
48. DeWilde J, Spiers R, Mertens C, et al. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993; 87: 141-5
49. Laws D, Ashford JJ, Anstee JA. A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice. Acta Psychiatr Scand 1990; 81: 185-9
50. Houck C, Stankovic S. An open-label study of fluvoxamine in outpatients with mixed anxiety-depressive disorder [poster no. 118]. 37th Annual meeting of the New Clinical Drug Evaluation Unit (NCDEU) program: 1997 May 27-30: Boca Raton
51. Carrasco JL, Diaz-Marsa M, Saiz J. Sertraline in the treatment of mixed anxiety and depression disorder [in Spanish]. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1997; 25 (3): 141-5
52. Boyer WF, Feighner JP. Side effects of the selective serotonin re-uplake inhibitors. In: Feighner JP, Boyer WF, editors. Selective serotonin re-uptake inhibitors. Chichester: John Wiley & Sons, 1991: 109-17
53. Bakish D, Hooper CL, Filteau M-J, et al. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacol Bull 1996; 32 (1): 135-41
54. Schneier F, Campeas R, Fallon B, et al. Buspirone in social phobia [abstract no. O-12-7-8]. Presented at the 17th Congress of Collegium Internationale Neuro-Psychpharmacologium: 1991 Sep 10-14, Kyoto
55. Schwiezer EE, Amsterdam J, Rickels K, et al. Open trial of buspirone in the treatment of major depressive disorder. Psychopharmacol Bull 1986; 22: 183-5
56. Fabre LF. Buspirone in the management of major depression: a placebo-controlled comparison. J Clin Psychiatry 1990; 51 Suppl. 9: 55-61
57. Sramek JJ, Tansman M, Suri A, et al. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. J Clin Psychiatry 1996; 57: 287-91
58. Sussman N. How to manage anxious patients who are depressed. J Clin Psychiatry 1993; 54 (5 Suppl.): 8-16
59. Rickels K, Robinson DS, Schweizer E, et al. Nefazodone: aspects of efficacy. J Clin Psychiatry 1995; 56 Suppl. 6: 43-6
60. Robinson DS, Roberts DL, Smith JM, et al. The safety profile of nefazodone. J Clin Psychiatry 1996; 57 Suppl. 2: 31-8
61. Fawcett J, Marcus RN, Anton SF, et al. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry 1995; 56 Suppl. 6: 37-42
62. Zajecka JM. The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. J Clin Psychiatry 1996; 57: 10-5
63. DeMartinis NA, Schweizer E, Rickels K. An open-label trial of nefazodone in high comorbidity panic disorder. J Clin Psychiatry 1996; 57: 245-8
64. Srewart JW, Quitkin FM, McGrath PJ. Nefazodone may relieve anxiety within two weeks in anxious-depressives [poster 119]. 37th Annual meeting of the New Clinical Drug Evaluation Unit (NCDEU) program: 1997 May 27-30; Boca Raton
65. Lydiard RB, Laraia MT, Ballenger JC, et al. Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. Am J Psychiatry 1987; 144: 664-5
66. Marks J. The benzodiazepines. Lancaster: MTP Press Limited. 1985: 100-5
67. Lecrubier Y, Bourin M, Moon CAL, et al. Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand 1997; 95: 485-93
68. Khan A, Upton V, Rudolph RL, et al. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. J Clin Psychopharmacol 1998; 18: 19-25
69. Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord 1998; 47: 55-62